Letrozol Tecnigen

Letrozole, the active ingredient in Letrozol Tecnigen, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women. The drug works by blocking estrogen synthesis, thereby limiting tumor growth driven by estrogen signaling.

GNH USA supplies Letrozol Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to EU quality standards and provides regulatory documentation to facilitate import and distribution in multiple markets.

Letrozole is an aromatase inhibitor used in hormone‑dependent breast cancer management.

- Adjuvant therapy: reduces risk of cancer recurrence after surgery in postmenopausal women with hormone receptor‑positive breast cancer. - Metastatic disease: slows disease progression and improves survival in patients with advanced hormone receptor‑positive breast cancer. - Neoadjuvant therapy: may shrink tumors before surgery, facilitating breast‑conserving procedures in eligible postmenopausal patients.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: transient feeling of warmth and sweating. - Joint and muscle pain: arthralgia or myalgia affecting daily activities. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects: - Severe osteoporosis: increased risk of bone fractures requiring monitoring. - Cardiovascular events: rare cases of myocardial infarction or stroke. - Liver dysfunction: elevated transaminases or hepatitis.

When prescribing Letrozole, clinicians should consider several safety measures to minimize risks.

- Assess bone health: perform baseline densitometry and consider calcium/vitamin D supplementation. - Monitor liver function: check transaminases periodically during therapy. - Evaluate cardiovascular risk: review history of thromboembolic disease before initiation. - Avoid use in premenopausal women: drug is ineffective without ovarian suppression. - Inform patients about potential hot flashes and joint pain and advise reporting severe symptoms. - Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Letrozole can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce plasma levels of letrozole. - Tamoxifen: concurrent use can antagonize aromatase inhibition and affect therapeutic outcome. - Estrogen‑containing hormone therapy: opposes the intended estrogen‑lowering effect.

Moderate Interactions (Monitor Closely): - Warfarin: letrozole may enhance anticoagulant effect, requiring INR monitoring. - Selective serotonin reuptake inhibitors (SSRIs): may increase risk of bone loss. - Glucocorticoids: additive effect on bone density reduction.